Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Adamas Pharma (ADMS)

Adamas Pharma (ADMS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 72,554
  • Shares Outstanding, K 28,013
  • Annual Sales, $ 54,640 K
  • Annual Income, $ -105,190 K
  • 60-Month Beta 1.88
  • Price/Sales 1.36
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -0.77
  • Number of Estimates 5
  • High Estimate -0.60
  • Low Estimate -0.91
  • Prior Year -1.08
  • Growth Rate Est. (year over year) +28.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.90 +36.32%
on 03/18/20
4.37 -40.73%
on 03/04/20
-1.39 (-34.92%)
since 03/03/20
3-Month
1.90 +36.32%
on 03/18/20
6.13 -57.75%
on 01/21/20
-1.51 (-36.83%)
since 01/03/20
52-Week
1.90 +36.32%
on 03/18/20
7.78 -66.71%
on 09/23/19
-4.31 (-62.46%)
since 04/03/19

Most Recent Stories

More News
Adamas Pharmaceuticals Stock - Kehoe Law Firm, P.C. Investigating Breach of Fiduciary Duty Claims on Behalf of ADMS Investors - ADMS Shareholders Encouraged to Contact Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is investigating breach of fiduciary duty claims on behalf of shareholders of Adamas Pharmaceuticals, Inc. (NasdaqGM: ADMS) that presently own the common stock of Adamas Pharmaceuticals,...

ADMS : 2.59 (-2.26%)
Adamas Pharmaceuticals Stock - Kehoe Law Firm, P.C. Investigating Breach of Fiduciary Duty Claims on Behalf of ADMS Investors - ADMS Shareholders Encouraged to Contact Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is investigating breach of fiduciary duty claims on behalf of shareholders of Adamas Pharmaceuticals, Inc. (NasdaqGM: ADMS) that presently own the common stock of Adamas Pharmaceuticals,...

ADMS : 2.59 (-2.26%)
Adamas Announces New Employment Inducement Grant

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company's board of directors granted six new employees the option to purchase an aggregate of 70,000 shares...

ADMS : 2.59 (-2.26%)
Adamas Pharmaceuticals (ADMS) Reports Q4 Loss, Tops Revenue Estimates

Adamas (ADMS) delivered earnings and revenue surprises of 6.74% and 0.26%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

ADMS : 2.59 (-2.26%)
Adamas: 4Q Earnings Snapshot

EMERYVILLE, Calif. (AP) _ Adamas Pharmaceuticals Inc. (ADMS) on Tuesday reported a loss of $23.1 million in its fourth quarter.

ADMS : 2.59 (-2.26%)
Cronos (CRON) to Report Q4 Earnings: What's in the Cards?

Investors will focus on Cronos' (CRON) regular top- and bottom-line numbers, along with its pipeline progress, when it reports Q4 results.

ADMS : 2.59 (-2.26%)
ADRO : 2.54 (+1.20%)
VCEL : 8.50 (-1.39%)
CRON : 5.52 (+1.85%)
Adamas to Present at Upcoming Healthcare Conferences

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affected by neurological diseases, today announced...

ADMS : 2.59 (-2.26%)
Adamas to Announce Fourth Quarter 2019 Financial Results and Host Conference Call on February 25, 2020

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2019 fourth quarter financial results on Tuesday, February 25, 2020, after market close. Subsequently, Adamas' management...

ADMS : 2.59 (-2.26%)
4.4% Return Seen to Date on SmarTrend Adamas Pharmaceu Call (ADMS)

SmarTrend identified an Uptrend for Adamas Pharmaceu (NASDAQ:ADMS) on January 9th, 2020 at $5.38. In approximately 1 month, Adamas Pharmaceu has returned 4.37% as of today's recent price of $5.61.

ADMS : 2.59 (-2.26%)
Adamas To Present Analysis of Clinical Trials on GOCOVRI(R) Treatment at the 3rd Pan American Parkinson's Disease and Movement Disorders Congress

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affected by neurological diseases, announced...

ADMS : 2.59 (-2.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade ADMS with:

Business Summary

Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone...

See More

Key Turning Points

2nd Resistance Point 2.79
1st Resistance Point 2.69
Last Price 2.59
1st Support Level 2.49
2nd Support Level 2.39

See More

52-Week High 7.78
Fibonacci 61.8% 5.53
Fibonacci 50% 4.84
Fibonacci 38.2% 4.15
Last Price 2.59
52-Week Low 1.90

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar